# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousan...
Ascendiant Capital analyst Edward Woo reiterates IGC Pharma (AMEX:IGC) with a Buy and maintains $3.25 price target.
-- Study Deepens Understanding of Treatments for Alzheimer's Patients, Enabling More Effective Treatments --
https://subscriber.politicopro.com/article/2024/05/justice-department-poised-to-post-plans-for-marijuana-reclassification-00158...